Meeting
2012 ASCO Annual Meeting
Phase I study of oral rigosertib in patients with advanced solid tumors.
Authors
Daniel W. Bowles
Division of Medical Oncology, University of Colorado Denver, Aurora, CO
Daniel W. Bowles , Jennifer Robinson Diamond , Elaine Tat Lam , Wells A. Messersmith , Colin D. Weekes , Stephen Leong , Lia Gore , Christopher Hanyoung Lieu , Elizabeth Freas , Chen Ren , Francois Wilhelm , S. Gail Eckhardt , Antonio Jimeno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
New Targets, New Technologies
Clinical Trial Registration Number
NCT01168011
Citation
J Clin Oncol 30, 2012 (suppl; abstr 3017)
DOI
10.1200/jco.2012.30.15_suppl.3017
Abstract #
3017
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours.
First Author: Rosalind Margaret Glasspool
Poster
2013 ASCO Annual Meeting
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.
First Author: Gregory Lawrence Beatty
Poster
2012 ASCO Annual Meeting
Phase I study of weekly oral docetaxel (ModraDoc001) plus ritonavir in patients with advanced solid tumors.
First Author: Serena Marchetti
Poster
2023 ASCO Annual Meeting
Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.
First Author: Funda Meric-Bernstam